

ASX ANNOUNCEMENT

12 August 2020

Respiri Partners with Australian Patients Association for wheezo® real-world study

Respiri Limited (ASX:RSH) (“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health management, is pleased to announce a partnership with the Australian Patients Association (APA) to support patients living with asthma through Respiri’s wheezo Experiential Program (a real-world asthma management study). The APA are connected with 1.1 million Australian patients and 15,000 Health Care Practitioners.

The wheezo Experiential Program is a real-world study providing asthma patients and doctors access to Respiri’s revolutionary smart technology to monitor and log their wheeze, asthma symptoms, medication usage and importantly, digitise their asthma action plans.

“The APA is dedicated to championing and protecting the rights and interests of all patients and improving overall patient care and health outcomes. We are keen to support this study and see wheezo utilised in the real-world, tested by patients and their doctors, so that we can better understand the role it plays in asthma management and improvements in individual asthma care” says Stephen Mason CEO of the APA.

“Respiri welcomes APA’s support of our real-world study. It is a win for both organisations as our values are aligned on improving health outcomes for patients. Having patients participate in our real-world study and using our platform, is very valuable and will allow us to evolve the platform to truly meet the needs of asthma patients and extend asthma care beyond the clinic” said Mr Marjan Mikel, CEO and Managing Director of Respiri.

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

This ASX announcement dated 12 August 2020 has been authorised for release by the Board of Directors of Respiri Limited.

About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo® product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit www.respi.co

About wheezo®

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo device records wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

About the Australian Patients Association (APA)

The APA is an independent charity dedicated to supporting patients and championing and protecting the rights and interest of all Australian patients. Improving overall patient care and achieving better patient health. The APA is the VOICE of patients in Australia and was established to represent patients' interests, promote patient issues, and improve patients' outcomes. We believe that an effective patient support group, working on behalf of patients can have a proactive influence upon and effect positive change to patient care throughout Australia.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.